26.46 USD
-0.32 (-1.19%)
26.46 USD
0 (0%)
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 191 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. This makes AMPH very considerable for value investing!
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
Each year in the past 5 years AMPH has been profitable.
Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
AMPH has a better Return On Assets (6.70%) than 87.96% of its industry peers.
AMPH has a better Return On Equity (14.37%) than 88.48% of its industry peers.
AMPH's Return On Invested Capital of 8.51% is amongst the best of the industry. AMPH outperforms 86.91% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.85%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
The Profit Margin of AMPH (15.43%) is better than 87.43% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
AMPH's Operating Margin of 20.73% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
AMPH has a better Gross Margin (49.36%) than 64.40% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
The debt/assets ratio for AMPH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.40 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.40) is better than 62.30% of its industry peers.
The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
AMPH has a better Debt to FCF ratio (5.49) than 81.68% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
AMPH has a worse Debt to Equity ratio (0.78) than 71.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.4 |
ROIC/WACC0.96
WACC8.9%
2.3 Liquidity
AMPH has a Current Ratio of 3.12. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH's Current ratio of 3.12 is in line compared to the rest of the industry. AMPH outperforms 53.40% of its industry peers.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.21, AMPH is in line with its industry, outperforming 46.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
The Earnings Per Share has been growing by 61.62% on average over the past years. This is a very strong growth
AMPH shows a decrease in Revenue. In the last year, the revenue decreased by -0.03%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMPH is valuated cheaply with a Price/Earnings ratio of 7.69.
AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.72% of the companies in the same industry.
When comparing the Price/Earnings ratio of AMPH to the average of the S&P500 Index (26.60), we can say AMPH is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.09, the valuation of AMPH can be described as very cheap.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.23.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.69 | ||
| Fwd PE | 7.09 |
4.2 Price Multiples
AMPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPH is cheaper than 91.62% of the companies in the same industry.
AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.95 | ||
| EV/EBITDA | 7.35 |
4.3 Compensation for Growth
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
26.46
-0.32 (-1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners74.02%
Inst Owner Change0%
Ins Owners9.38%
Ins Owner Change0%
Market Cap1.22B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts80
Price Target32.35 (22.26%)
Short Float %11.45%
Short Ratio9.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-2.12%
PT rev (3m)-4.47%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)1.91%
EPS NY rev (1m)-0.07%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.69 | ||
| Fwd PE | 7.09 | ||
| P/S | 1.68 | ||
| P/FCF | 10.95 | ||
| P/OCF | 7.98 | ||
| P/B | 1.57 | ||
| P/tB | 5.95 | ||
| EV/EBITDA | 7.35 |
EPS(TTM)3.44
EY13%
EPS(NY)3.73
Fwd EY14.1%
FCF(TTM)2.42
FCFY9.13%
OCF(TTM)3.31
OCFY12.52%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.12
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.4 |
F-Score5
WACC8.9%
ROIC/WACC0.96
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7.69 and the Price/Book (PB) ratio is 1.57.